GSK won U.S. approval for second lung cancer drug from Nuvalent deal
GSK's neladalkib received FDA approval for treating ALK-positive non-small cell lung cancer. The drug was acquired through GSK's $10.6B Nuvalent deal. GSK's oncology sales rose 23% in Q3 to £600M. CEO Miels highlighted recent approvals, including Jideytro and Jemperli.
How this was made

The 30-second read
Why it matters
This is a direct regulatory milestone that converts acquired pipeline assets into U.S. commercial products, potentially improving oncology revenue trajectory and validating GSKs oncology re-entry strategy.
Market read
Traders can update expectations for GSKs oncology commercialization from the Nuvalent portfolio following FDA clearance.
What to watch
The article notes a later-phase trial is still ongoing; reimbursement, uptake speed, and confirmatory trial outcomes could drive the next valuation inflection more than the initial clearance.
Background
GSK acquired Nuvalent for $10.6B, bringing in lung cancer kinase inhibitors; the FDA has now cleared neladalkib (and previously Jideytro) for specific ALK/ROS1-positive NSCLC patient populations.
Ticker impact
FDA cleared GSKs neladalkib for ALK-positive metastatic or locally advanced NSCLC, extending targeted-therapy options for previously treated patients.
Likely positive repricing as investors update the probability-weighted contribution of Nuvalent assets to GSKs oncology return.
The article is a direct FDA approval for a drug acquired via the $10.6B Nuvalent deal, which is a concrete, tradable catalyst for GSKs pipeline commercialization.
Market effects
Reinforces demand for next-generation ALK/ROS1 kinase inhibitors and may increase competitive pressure on existing targeted-therapy franchises.
Primarily U.S. commercialization upside for GSK oncology assets, with potential follow-on updates to U.S. specialty medicine guidance.
Supports GSKs broader oncology re-entry narrative, which can influence global investor sentiment toward its pipeline execution.
Counterpoint
Accelerated approval is based on early-stage effects, so investors may discount near-term revenue durability until later-phase efficacy readouts mature.
Key entities
- companyGSK
Sponsor of neladalkib after acquiring Nuvalent; now has FDA clearance for ALK-positive metastatic or locally advanced NSCLC.
- regulatorFDA
Cleared neladalkib for adults with ALK-positive NSCLC after prior ALK inhibitor and/or chemotherapy exposure.
- companyNuvalent
Acquired by GSK; deal source for neladalkib and other lung cancer assets.




